CYAD — Celyad Oncology SA Share News
0.000.00%
Last trade - 00:00- €9.93m
- €9.80m
- €0.02m
Brief: Celyad Announces Pricing of $20.0 Million Global Offering
Brief: Celyad SA - Intends To Offer & Sell Up To 2 Million Ordinary Shares In A Global Offering
Brief: Celyad: Updates on CYAD-01 Produced with OptimAb Manufacturing Process
Brief: Celyad H1 Operating Loss Narrows To EUR 15.9 Mln
Brief: Celyad Reports Half Year 2019 Financial Results And Second Quarter Business Highlights
Advisory: Dated alert on Celyad update on therapies in solid tumors withdrawn
Celyad SA rises as FDA permits clinical testing of cancer therapy
Brief: Celyad Announces Strategic Updates To The Autologous R/R Aml And Mds Program
Brief: Celyad Updates On Cyad-01
Brief: Celyad Announces Q1 2019 Financial Results And Recent Business Highlights
Brief: Celyad Loss For The Year Narrows To 37.4 Million Euros
Brief: Celyad SA Appoints Filippo Petti As Chief Executive Officer (CEO) Of Celyad Effective April 1, 2019.
Brief: Celyad To Accelerate CYAD-01 Program In R/R AML And MDS
Brief: Celyad Presents Update On CYAD-01 Hematological Malignancies Program
Brief: Celyad Doses First MCRC Patient In The Phase 1 AlloSHRINK Trial
Brief: Celyad Ended Q3 With 55.9 Million Euros In Cash, Cash Equivalents And Short-Term investments
NASDAQ RESUMED
Brief: Celyad: Update On CYAD-01 Solid Tumor Clinical Program
NASDAQ TRADE HALT HALT NEWS PENDING